点击下方 卡片 ，关注" 具身智能 之心 "公众号 一、你的3D Grounding 模型真的work吗？ 在具身智能系统中，智能体需要依靠第一视角的3D感知算法来理解周边环境。作为其中的核心任务之一，Embodied 3D Grounding是指根据ego-centric的RGB- D图像序列以及语言描述在三维空间中定位目标对象，要求模型能够融合语言与三维视觉信息，准确识别出语句中所指代的物体。当前主流方法多采用两阶段策 略，即先利用检测模型提取三维区域特征，再进行语言引导的grounding微调。这自然引出一个疑问： 第二阶段这种针对 Grounding 的微调，其效果究竟如何，它 真的work吗？ 令人颇感意外的是，实证结果显示，即便是当前最先进的Grounding模型，其实际表现也远未达到预期。相反，那些完全未接受语言监督、仅依赖目标类别进行筛 选的检测模型，在Grounding任务的评估中竟取得了更优的结果。具体而言，考虑到任务中的语言指令为模板生成，本文通过规则解析提取出目标物体的类别标 签，之后使用该类别从检测模型中筛选对应预测框，直接作为Grounding的输出。理论上，这种做法缺乏语言理解过 ...

智谱是数家试图在全球与OpenAI竞争的中国初创公司之一，据此前提交中国证监会的备案文件，公司 最初准备在内地上市。 智谱，致力于打造新一代认知智能大模型，专注于做大模型的中国创新。公司合作研发了中英双语千亿 级超大规模预训练模型GLM-130B，并基于此推出对话模型ChatGLM，开源单卡版模型ChatGLM-6B。 同时，团队还打造了AIGC模型及产品矩阵，包括AI提效助手智谱清言(chatglm.cn)、高效率代码模型 CodeGeeX、多模态理解模型CogVLM和文生图模型CogView等。公司践行Model as a Service(MaaS)的市 场理念，推出大模型MaaS开放平台(https://open.bigmodel.cn/)，打造高效率、通用化的"模型即服务"AI 开发新范式。通过认知大模型链接物理世界的亿级用户，智谱基于完整的模型生态和全流程技术支持， 为千行百业带来持续创新与变革，加速迈向通用人工智能的时代。 来源：瑞恩资本RyanbenCapital 中国「AI六小虎」之一的北京智谱华章科技股份有限公司(简称"智谱")据报考虑将其IPO计划的地点由 内地改为香港，料将为香港新股热潮 ...

Core Insights - Northern Technologies International Corporation (NTIC) reported a 4.0% increase in consolidated net sales for Q3 fiscal 2025, reaching $21.51 million compared to $20.69 million in Q3 fiscal 2024, driven by demand for ZERUST® industrial products despite geopolitical tensions [4][6][20] - The company continues to invest in its ZERUST® oil and gas business, expecting sequential growth in sales and profitability in Q4 fiscal 2025 and into fiscal 2026, with cumulative sales of $24 million over the past 13 quarters [2][3] - NTIC is monitoring European economic stimulus packages, particularly in Germany, which may positively impact joint venture operating income [3] Financial Performance - Consolidated net sales for the nine months ended May 31, 2025, increased by 0.3% to $61.92 million from $61.71 million in the same period last year [4][20] - ZERUST® industrial net sales rose by 7.1% to $14.44 million, while ZERUST® oil and gas net sales decreased by 5.3% to $1.29 million [5][6] - Gross profit margin increased by 20 basis points to 38.4%, while operating expenses rose by 7.6% to $9.67 million [6][7] Income and Earnings - Net income attributable to NTIC for Q3 fiscal 2025 was $122,000, or $0.01 per diluted share, down from $977,000, or $0.10 per diluted share, in Q3 fiscal 2024 [9][21] - Year-to-date net income attributable to NTIC was $1.12 million, or $0.12 per diluted share, compared to $3.57 million, or $0.36 per diluted share, for the same period last year [9][21] - Non-GAAP adjusted net income for Q3 fiscal 2025 was $228,000, or $0.02 per diluted share, compared to $1.08 million, or $0.11 per diluted share, for the same quarter last fiscal year [10][25] Joint Ventures and Investments - NTIC's joint venture operating income decreased by 12.9% to $2.27 million in Q3 fiscal 2025, primarily due to lower sales and reduced equity income from joint ventures [7][20] - The company had $27.14 million in investments in joint ventures as of May 31, 2025, with $13.50 million in cash [12][18] Balance Sheet Highlights - As of May 31, 2025, NTIC had working capital of $21.66 million, including $6.77 million in cash and cash equivalents [11][18] - Total assets increased to $99.30 million from $94.68 million as of August 31, 2024 [18][19]

Presented updated data for bexobrutideg (NX-5948) at EHA2025 and ICML-18, demonstrating a favorable safety profile and deepening responses in patients with r/r chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia (WM) Secured $15M license fee as Sanofi extends STAT6 collaboration to target type 2 inflammatory diseases Announced FDA clearance of IND application for novel IRAK4 degrader GS-6791/NX-0479, enabling collaboration partner Gilead to initiate Phase 1 trial Well capitalized with cash ...

– John Houston, Ph.D., Chairperson, CEO and President at Arvinas, Announces Plans to Retire as CEO Upon Appointment of Successor – – Dr. Houston to Remain Chairperson of Arvinas Board of Directors – About Arvinas Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to h ...

1000x tokenized stock trading 🤯Aevo (@aevoxyz):🚨What if you could 1000x your favorite stonk?Introducing Aevo Degen: The first and only platform offering 1000x leverage on equities.Go long or short on @coinbase ($COIN), @RobinhoodApp ($HOOD), and @circle ($CRCL).More pairs coming soon!Heads up: These are daily https://t.co/5a47ZwctOW ...

网络安全早已超越了单一技术范畴，成为现代社会有序运转不可或缺的空气与水，并直接关乎公众信任、社会稳定乃 至国家安全这一最高级别的社会责任。 在7月4日至5日举行的"格隆汇·全球投资嘉年华"上，奇安信凭借其在ESG领域的卓越实践，荣获"金格奖"年度"ESG社 会责任卓越企业"奖项。 作为网络安全国家队，奇安信始终将网络安全建设置于重要战略位置，并坚持科技向善的理念。凭借着将网络安全技 术之力与社会责任之魂深度融合，奇安信构筑起守护国家网络和数字安全的坚固屏障。 一、护航国家级盛会，赋能企业数字化转型 奇安信的核心竞争力源于对社会深层安全需求的精准响应。 一方面，作为网络安全领域的国家队，奇安信一直以领先的技术实力为国家重大活动保驾护航。截至2024年，奇安信 累计完成87次国家重要活动网络安全保障任务，包括建党100周年、国庆70周年、党的"二十大"等重大活动。 2022年北京冬奥会及冬残奥会期间，奇安信依托全维度管控、全网络防护、全天候运行、全领域覆盖、全兵种协同、 全线索闭环的"六全"网络安全防护体系，首次实现奥运史上网络安全"零事故"目标。这一成就不仅为奇安信赢得了荣 誉，更成为国家级活动安全的新标准。 ...

Bexobrutideg Clinical Trial Updates - Bexobrutideg demonstrates rapid and durable clinical responses in relapsed/refractory CLL, with updated findings from an ongoing Phase 1a study presented at EHA 2025[5,9] - Bexobrutideg shows high clinical activity and tolerable safety in an ongoing Phase 1a/b study in patients with Waldenström macroglobulinemia (WM)[5,9] - In CLL patients, the objective response rate (ORR) was 80.9% (95% CI: 66.7–90.9), with 1 (2.1%) complete response (CR) and 37 (78.7%) partial responses (PR)[24] - In WM patients, the objective response rate (ORR) was 84.2%, with 2 (10.5%) very good partial responses (VGPR) and 11 (57.9%) partial responses (PR)[47] Bexobrutideg Safety and Tolerability - Bexobrutideg is well-tolerated in patients with relapsed/refractory CLL, with purpura/contusion (45.8%), diarrhea (31.3%), and fatigue (31.3%) being the most common treatment-emergent adverse events (TEAEs)[22] - In WM patients, the most common TEAEs were petechiae (27.3%), diarrhea (22.7%), and purpura/contusion (18.2%), with a favorable safety profile and no new safety signals[45] Bexobrutideg Mechanism and Market Potential - Bexobrutideg is a novel small molecule BTK degrader that can overcome treatment-emergent BTKi resistance mutations and disrupt BTK scaffolding[15,54] - The total BTKi sales were $10.6 billion in 2024 and projected worldwide sales for BTK-targeting agents in CLL are expected to exceed $15 billion by 2028[75] - Nurix is advancing bexobrutideg in CLL with a first pivotal study to be initiated in 2025, positioned to lead a new class of therapeutics in CLL[66] Regulatory Designations - Bexobrutideg has received U S Fast Track Designation from the FDA for CLL (January 2024) and WM (December 2024)[62,61] - Bexobrutideg has received EU PRIME designation from EMA in November 2024[62]

NFT Market Trend - DeGods has become the profile picture of fake follower engagement farmers [1]

TABER, ALBERTA, July 01, 2025 (GLOBE NEWSWIRE) -- FLEXIBLE SOLUTIONS INTERNATIONAL, INC. (NYSE Amex: FSI), is the developer and manufacturer of biodegradable polymers for oil extraction, detergent ingredients and water treatment as well as crop nutrient availability chemistry. Flexible Solutions also manufactures biodegradable and environmentally safe water and energy conservation technologies. FSI is also increasing its presense in the food and nutrition supplement manufacturing markets. Today the Company ...